|
|||||
|
|
Malleability of the SARS-CoV-2 3CL Mpro Active-Site Cavity Facilitates Binding of Clinical Antivirals |
|
| Institution: | 1. Neutron Scattering Division, Oak Ridge National Laboratory, 1 Bethel Valley Road, Oak Ridge, TN 37831, USA;2. National Virtual Biotechnology Laboratory, US Department of Energy, Washington, DC, USA;3. Biosciences Division, Oak Ridge National Laboratory, 1 Bethel Valley Road, Oak Ridge, TN 37831, USA;4. Second Target Station, Oak Ridge National Laboratory, 1 Bethel Valley Road, Oak Ridge, TN 37831, USA |
| Abstract: |  |
| Keywords: | room temperature X-ray crystallography SARS-CoV-2 3CL main protease protease inhibitor hepatitis C clinical drugs enzyme kinetics drug design repurposing clinical drugs |
| 本文献已被 ScienceDirect 等数据库收录！ | |